Patients with POLE mutations have also been described in the literature to have a significant response to immune checkpoint inhibition, and cancers harboring POLE mutations are good candidates for treatment with immune checkpoint inhibitors, increasing the likelihood that conservative treatment will be available for younger patients. The gene discussed is POLE; the disease is cancer.